carbamates has been researched along with Hepatocellular Carcinoma in 50 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Areas covered: This review covers the preclinical and clinical development of sofosbuvir/velpatasvir (SOF/VEL), an interferon-free, once daily, pangenotypic treatment for the treatment of chronic hepatitis C virus (HCV) infection." | 8.95 | A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection. ( Jacobson, IM; Weisberg, IS, 2017) |
| " The study included patients from 16 hepatologic centres involved in the AMBER, investigator-initiated study on treatment of chronic hepatitis C patients within a programme preceding EU registration of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin." | 7.88 | Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real-world experience study. ( Berak, H; Białkowska, J; Bolewska, B; Fleischer-Stępniewska, K; Flisiak, R; Garlicki, A; Janczewska, E; Karpińska, E; Karwowska, K; Nazzal, K; Piekarska, A; Simon, K; Tomasiewicz, K; Tronina, O; Tuchendler, E; Zarębska-Michaluk, D; Łucejko, M, 2018) |
| "We observed a sustained viral response (SVR) of ombitasvir/paritaprevir/ritonavir, dasabuvir and ribavirin therapy, for 12 wk, in two cases with compensated liver cirrhosis and fully destroyed early hepatocellular carcinoma (HCC)." | 7.83 | Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma. ( Antonov, K; Atanasova, E; Boyanova, Y; Jelev, D; Krastev, Z; Mateva, L; Petkova, T; Tomov, B; Zheleva, N, 2016) |
| "The efficacy of the all-oral administration of daclatasvir and asunaprevir for 24 weeks was compared with that of telaprevir for 12 weeks plus pegylated interferon and ribavirin (PEG-IFN/RBV) for 24 weeks, and that of simeprevir for 12 weeks plus PEG-IFN/RBV for 24 weeks, with a focus on the prevention of occurrence and recurrence of hepatocellular carcinoma (HCC)." | 7.81 | Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma. ( Hatae, T; Hayashi, Y; Imoto, S; Kim, KI; Kim, SK; Kim, SR; Kudo, M; Ohtani, A; Sugimoto, K; Tohyama, M; Yano, Y, 2015) |
| "The risk of hepatocellular carcinoma (HCC) development is reduced following viral elimination by interferon therapy in chronic hepatitis C patients." | 5.46 | The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy. ( Aikata, H; Chayama, K; Daijo, K; Fujino, H; Hatooka, M; Hayes, CN; Hiramatsu, A; Honda, F; Imamura, M; Kan, H; Kawakami, Y; Kawaoka, T; Kobayashi, T; Masaki, K; Miki, D; Morio, K; Morio, R; Nagaoki, Y; Nakahara, T; Nakamura, Y; Ochi, H; Ono, A; Teraoka, Y; Tsuge, M, 2017) |
| " Areas covered: This review covers the preclinical and clinical development of sofosbuvir/velpatasvir (SOF/VEL), an interferon-free, once daily, pangenotypic treatment for the treatment of chronic hepatitis C virus (HCV) infection." | 4.95 | A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection. ( Jacobson, IM; Weisberg, IS, 2017) |
| "In this study, the authors report the case of a patient diagnosed with hepatitis C virus who was treated with sofosbuvir-velpatasvir (400/100 mg)." | 3.96 | Therapeutic Drug Monitoring-Guided Crushed Sofosbuvir-Velpatasvir Treatment: A Case Study. ( Guyader, D; Jézéquel, C; Lalanne, S; Lemaitre, F; Mercerolle, M; Pronier, C; Tron, C; Verdier, MC, 2020) |
| " The study included patients from 16 hepatologic centres involved in the AMBER, investigator-initiated study on treatment of chronic hepatitis C patients within a programme preceding EU registration of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin." | 3.88 | Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real-world experience study. ( Berak, H; Białkowska, J; Bolewska, B; Fleischer-Stępniewska, K; Flisiak, R; Garlicki, A; Janczewska, E; Karpińska, E; Karwowska, K; Nazzal, K; Piekarska, A; Simon, K; Tomasiewicz, K; Tronina, O; Tuchendler, E; Zarębska-Michaluk, D; Łucejko, M, 2018) |
| " The patients were taking sorafenib for advanced hepatocellular carcinoma and received OBV/PTV/r+DSV for 12 weeks." | 3.88 | Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice. ( Giménez-Manzorro, A; Herranz-Alonso, A; Matilla-Peña, A; Revuelta-Herrero, JL; Sanjurjo-Sáez, M, 2018) |
| "We observed a sustained viral response (SVR) of ombitasvir/paritaprevir/ritonavir, dasabuvir and ribavirin therapy, for 12 wk, in two cases with compensated liver cirrhosis and fully destroyed early hepatocellular carcinoma (HCC)." | 3.83 | Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma. ( Antonov, K; Atanasova, E; Boyanova, Y; Jelev, D; Krastev, Z; Mateva, L; Petkova, T; Tomov, B; Zheleva, N, 2016) |
| "The efficacy of the all-oral administration of daclatasvir and asunaprevir for 24 weeks was compared with that of telaprevir for 12 weeks plus pegylated interferon and ribavirin (PEG-IFN/RBV) for 24 weeks, and that of simeprevir for 12 weeks plus PEG-IFN/RBV for 24 weeks, with a focus on the prevention of occurrence and recurrence of hepatocellular carcinoma (HCC)." | 3.81 | Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma. ( Hatae, T; Hayashi, Y; Imoto, S; Kim, KI; Kim, SK; Kim, SR; Kudo, M; Ohtani, A; Sugimoto, K; Tohyama, M; Yano, Y, 2015) |
| "The recurrent hepatocellular carcinoma enlarged quite rapidly and induced multiple peritoneal disseminations and lung metastases." | 1.56 | Hepatitis C virus relapse after successful treatment with direct-acting antivirals, followed by sarcomatous changes in hepatocellular carcinoma: a case report. ( Arai, J; Fukumura, Y; Imai, M; Kato, J; Kojima, K; Kondo, M; Kurokawa, K; Mori, M; Ohki, T; Seki, M; Shibata, C; Tagawa, K; Takagi, K; Toda, N, 2020) |
| "Furthermore, hepatocellular carcinoma (HCC) is known to dedifferentiate from hypovascular tumors, such as dysplastic nodules or well-differentiated HCC, to hypervascular tumors." | 1.56 | Hypovascular tumors developed into hepatocellular carcinoma at a high rate despite the elimination of hepatitis C virus by direct-acting antivirals. ( Fujisaki, K; Hashiguchi, M; Hiramine, Y; Hori, T; Ido, A; Ijuin, S; Imanaka, D; Inada, Y; Kanmura, S; Kumagai, K; Kure, T; Mawatari, S; Moriuchi, A; Oda, K; Saisyoji, A; Sakae, H; Sakurai, K; Tabu, K; Tamai, T; Taniyama, O; Toyodome, A; Uto, H, 2020) |
| " Most frequent adverse events included fatigue (6%), hyperbilirubinemia (6%) and anemia (4%)." | 1.51 | Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure. ( Aghemo, A; Alberti, A; Bonfanti, P; Carolo, G; Carriero, C; Centenaro, R; Degasperi, E; Fabris, P; Faggiano, G; Fagiuoli, S; Gatti, F; Giorgini, A; Grossi, G; Lampertico, P; Landonio, S; Lombardi, A; Lomonaco, L; Maggiolo, F; Noventa, F; Paolucci, S; Paon, V; Pasin, F; Pasulo, L; Pozzoni, P; Puoti, M; Romano, A; Rossi, MC; Rovere, P; Russo, FP; Soffredini, R; Soria, A; Spinetti, A; Vario, A; Vinci, M; Zoncada, A, 2019) |
| "Data are sparse on treatment of chronic hepatitis C virus (HCV) in cancer patients." | 1.51 | Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational Study. ( Angelidakis, G; Blechacz, B; Economides, MP; Granwehr, BP; Hosry, J; Jiang, Y; Kaseb, A; Kyvernitakis, A; Mahale, P; Miller, E; Naing, A; Raad, II; Samaniego, F; Torres, HA, 2019) |
| "Ascites and hepatic encephalopathy occurred in 10." | 1.48 | High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma. ( Aghemo, A; Aglitti, A; Andreone, P; Boccaccio, V; Bollani, S; Brunetto, MR; Bruno, S; Calvaruso, V; Ciancio, A; Coco, B; Conti, F; Degasperi, E; Di Leo, A; Di Marco, V; Giorgini, A; Lampertico, P; Lleo, A; Maisonneuve, P; Marzi, L; Persico, M; Rendina, M; Troshina, G; Villa, E; Zuin, M, 2018) |
| "The risk of hepatocellular carcinoma (HCC) development is reduced following viral elimination by interferon therapy in chronic hepatitis C patients." | 1.46 | The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy. ( Aikata, H; Chayama, K; Daijo, K; Fujino, H; Hatooka, M; Hayes, CN; Hiramatsu, A; Honda, F; Imamura, M; Kan, H; Kawakami, Y; Kawaoka, T; Kobayashi, T; Masaki, K; Miki, D; Morio, K; Morio, R; Nagaoki, Y; Nakahara, T; Nakamura, Y; Ochi, H; Ono, A; Teraoka, Y; Tsuge, M, 2017) |
| "At the age of 46, he was diagnosed with hepatocellular carcinoma with subsequent resection of the tumour in May 2015." | 1.46 | Successful twice interrupted therapy of HCV infection in patients with cirrhosis with hepatocellular carcinoma before and after liver transplantation. ( Rostkowska, K; Simon, K; Szymanek-Pasternak, A, 2017) |
| " Details of serious adverse events (SAEs) were recorded." | 1.46 | Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. ( Albillos, A; Ampuero, J; Arenas, J; Bañares, R; Calleja, JL; Crespo, J; Diago, M; Fernandez, I; García-Eliz, M; García-Samaniego, J; Gea, F; Jorquera, F; Lens, S; Llaneras, J; Llerena, S; Mariño, Z; Morillas, RM; Muñoz, R; Navascues, CA; Pascasio, JM; Perelló, C; Rincón, D; Rodriguez, CF; Ruiz-Antorán, B; Sacristán, B; Serra, MA; Simon, MA; Torras, X; Turnes, J, 2017) |
| "None of the patients had hepatocellular carcinoma before and during antiviral therapy." | 1.43 | Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals. ( Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y, 2016) |
| "Amprenavir was able to delay the growth of hepatocarcinoma xenografts in nude mice and had a synergistic effect with Doxorubicin." | 1.39 | Amprenavir inhibits the migration in human hepatocarcinoma cell and the growth of xenografts. ( Baldi, A; Chirianni, A; De Luca, A; Esposito, V; Galati, R; Manente, L; Montesarchio, V; Pagliano, P; Parrella, G; Parrella, R; Spugnini, EP; Verdina, A; Viglietti, R, 2013) |
| " Future investigation should address the possible hepatocarcinogenicity of pesticides using biomarkers of exposure and other techniques to better estimate dose-response relationships." | 1.33 | Associations of pesticides, HCV, HBV, and hepatocellular carcinoma in Egypt. ( Abdel-Hamid, A; Abdel-Hamid, M; Eissa, SA; El-Ghorory, L; Ezzat, S; Hifnawy, T; Labib, NA; Loffredo, CA; Mikhail, NN; Mokhtar, N; Strickland, GT, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (2.00) | 29.6817 |
| 2010's | 28 (56.00) | 24.3611 |
| 2020's | 11 (22.00) | 2.80 |
| Authors | Studies |
|---|---|
| Turgeon, MK | 1 |
| Shah, SA | 1 |
| Delman, AM | 1 |
| Tran, BV | 1 |
| Agopian, VG | 1 |
| Wedd, JP | 1 |
| Magliocca, JF | 1 |
| Kim, A | 1 |
| Cameron, A | 1 |
| Olyaei, A | 1 |
| Orloff, SL | 1 |
| Anderson, MP | 1 |
| Kubal, CA | 1 |
| Cannon, RM | 1 |
| Locke, JE | 1 |
| Simpson, MA | 1 |
| Akoad, ME | 1 |
| Wongjirad, CP | 1 |
| Emamaullee, J | 1 |
| Moro, A | 1 |
| Aucejo, F | 1 |
| Feizpour, CA | 1 |
| Vagefi, PA | 1 |
| Nguyen, MH | 1 |
| Esquivel, CO | 1 |
| Dhanireddy, K | 1 |
| Subramanian, V | 1 |
| Chavarriaga, A | 1 |
| Kazimi, MM | 1 |
| Anderson, MS | 1 |
| Sonnenday, CJ | 1 |
| Kim, SC | 1 |
| Foley, DP | 1 |
| Abdouljoud, M | 1 |
| Salgia, RJ | 1 |
| Moris, D | 1 |
| Sudan, DL | 1 |
| Ganesh, SR | 1 |
| Humar, A | 1 |
| Doyle, M | 1 |
| Chapman, WC | 1 |
| Maithel, SK | 1 |
| Ghanm, SE | 1 |
| Shebl, NA | 1 |
| El Sayed, IET | 1 |
| Abdel-Bary, HM | 1 |
| Saad, BF | 1 |
| Othman Saad, W | 1 |
| Yoo, HW | 1 |
| Park, JY | 1 |
| Kim, SG | 1 |
| Jung, YK | 1 |
| Lee, SH | 1 |
| Kim, MY | 1 |
| Jun, DW | 1 |
| Jang, JY | 1 |
| Lee, JW | 1 |
| Kwon, OS | 1 |
| Degasperi, E | 2 |
| Spinetti, A | 1 |
| Lombardi, A | 1 |
| Landonio, S | 1 |
| Rossi, MC | 1 |
| Pasulo, L | 1 |
| Pozzoni, P | 1 |
| Giorgini, A | 2 |
| Fabris, P | 1 |
| Romano, A | 1 |
| Lomonaco, L | 1 |
| Puoti, M | 2 |
| Vinci, M | 1 |
| Gatti, F | 1 |
| Carolo, G | 1 |
| Zoncada, A | 1 |
| Bonfanti, P | 1 |
| Russo, FP | 1 |
| Aghemo, A | 2 |
| Soria, A | 1 |
| Centenaro, R | 1 |
| Maggiolo, F | 1 |
| Rovere, P | 1 |
| Pasin, F | 1 |
| Paon, V | 1 |
| Faggiano, G | 1 |
| Vario, A | 1 |
| Grossi, G | 1 |
| Soffredini, R | 1 |
| Carriero, C | 1 |
| Paolucci, S | 1 |
| Noventa, F | 1 |
| Alberti, A | 1 |
| Lampertico, P | 2 |
| Fagiuoli, S | 1 |
| Merli, M | 1 |
| Rossotti, R | 1 |
| Travi, G | 1 |
| Ferla, F | 1 |
| Lauterio, A | 1 |
| Angelini Zucchetti, T | 1 |
| Alcantarini, C | 1 |
| Bargiacchi, O | 1 |
| De Carlis, L | 1 |
| Brustolin, L | 1 |
| Pettenuzzo, N | 1 |
| Nardon, C | 1 |
| Quarta, S | 1 |
| Marchiò, L | 1 |
| Biondi, B | 1 |
| Pontisso, P | 1 |
| Fregona, D | 1 |
| Holmes, JA | 1 |
| Chung, RT | 1 |
| Lalanne, S | 1 |
| Jézéquel, C | 1 |
| Tron, C | 1 |
| Verdier, MC | 1 |
| Mercerolle, M | 1 |
| Pronier, C | 1 |
| Guyader, D | 1 |
| Lemaitre, F | 1 |
| Tayyab, GUN | 1 |
| Rasool, S | 1 |
| Nasir, B | 1 |
| Rubi, G | 1 |
| Abou-Samra, AB | 1 |
| Butt, AA | 1 |
| Kurokawa, K | 1 |
| Ohki, T | 1 |
| Kato, J | 1 |
| Fukumura, Y | 1 |
| Imai, M | 1 |
| Shibata, C | 1 |
| Arai, J | 1 |
| Kondo, M | 1 |
| Takagi, K | 1 |
| Kojima, K | 1 |
| Seki, M | 1 |
| Mori, M | 1 |
| Toda, N | 1 |
| Tagawa, K | 1 |
| Tabu, K | 1 |
| Mawatari, S | 1 |
| Oda, K | 1 |
| Kumagai, K | 1 |
| Inada, Y | 2 |
| Uto, H | 1 |
| Saisyoji, A | 1 |
| Hiramine, Y | 1 |
| Hashiguchi, M | 1 |
| Tamai, T | 1 |
| Hori, T | 1 |
| Fujisaki, K | 1 |
| Imanaka, D | 1 |
| Kure, T | 1 |
| Taniyama, O | 1 |
| Toyodome, A | 1 |
| Ijuin, S | 1 |
| Sakae, H | 1 |
| Sakurai, K | 1 |
| Moriuchi, A | 1 |
| Kanmura, S | 1 |
| Ido, A | 2 |
| Chan, J | 1 |
| Kim, JJ | 1 |
| Barrett, BK | 1 |
| Hamadeh, A | 1 |
| Feld, JJ | 1 |
| Wong, WWL | 1 |
| Cheng, TS | 1 |
| Liang, PC | 1 |
| Huang, CF | 1 |
| Yeh, ML | 1 |
| Huang, CI | 1 |
| Lin, ZY | 1 |
| Chen, SC | 1 |
| Huang, JF | 1 |
| Dai, CY | 1 |
| Hsieh, PH | 1 |
| Chuang, WL | 1 |
| Yu, ML | 1 |
| Li, J | 1 |
| Zhou, Q | 1 |
| Rong, L | 1 |
| Rong, D | 1 |
| Yang, Y | 1 |
| Hao, J | 1 |
| Zhang, Z | 1 |
| Ma, L | 1 |
| Rao, G | 1 |
| Zhou, Y | 1 |
| Xiao, F | 1 |
| Li, C | 1 |
| Wang, H | 1 |
| Li, YP | 2 |
| Shimizu, H | 1 |
| Matsui, K | 1 |
| Iwabuchi, S | 1 |
| Fujikawa, T | 1 |
| Nagata, M | 1 |
| Takatsuka, K | 1 |
| Tanemura, H | 1 |
| Nakazaki, H | 1 |
| Nakano, M | 1 |
| Watanabe, T | 1 |
| Nagaoki, Y | 1 |
| Imamura, M | 1 |
| Aikata, H | 1 |
| Daijo, K | 1 |
| Teraoka, Y | 1 |
| Honda, F | 1 |
| Nakamura, Y | 1 |
| Hatooka, M | 1 |
| Morio, R | 1 |
| Morio, K | 1 |
| Kan, H | 1 |
| Fujino, H | 1 |
| Kobayashi, T | 1 |
| Masaki, K | 1 |
| Ono, A | 1 |
| Nakahara, T | 1 |
| Kawaoka, T | 1 |
| Tsuge, M | 1 |
| Hiramatsu, A | 1 |
| Kawakami, Y | 1 |
| Hayes, CN | 1 |
| Miki, D | 1 |
| Ochi, H | 1 |
| Chayama, K | 2 |
| Szymanek-Pasternak, A | 1 |
| Rostkowska, K | 1 |
| Simon, K | 2 |
| Ida, H | 1 |
| Hagiwara, S | 1 |
| Kono, M | 1 |
| Minami, T | 1 |
| Chishina, H | 1 |
| Arizumi, T | 1 |
| Takita, M | 1 |
| Yada, N | 1 |
| Minami, Y | 1 |
| Ueshima, K | 1 |
| Nishida, N | 1 |
| Kudo, M | 2 |
| Beinhardt, S | 1 |
| Al-Zoairy, R | 1 |
| Kozbial, K | 1 |
| Stättermayer, AF | 1 |
| Maieron, A | 1 |
| Stauber, R | 1 |
| Strasser, M | 1 |
| Zoller, H | 1 |
| Graziadei, I | 1 |
| Rasoul-Rockenschaub, S | 1 |
| Trauner, M | 1 |
| Ferenci, P | 1 |
| Hofer, H | 1 |
| Akuta, N | 2 |
| Toyota, J | 1 |
| Karino, Y | 1 |
| Ikeda, F | 1 |
| Tanaka, K | 1 |
| Takaguchi, K | 1 |
| Naganuma, A | 1 |
| Tomita, E | 1 |
| Fujiyama, S | 2 |
| Yoshiji, H | 1 |
| Watanabe, H | 1 |
| Ishikawa, H | 1 |
| McPhee, F | 1 |
| Noviello, S | 1 |
| Kumada, H | 2 |
| Persico, M | 1 |
| Aglitti, A | 1 |
| Rendina, M | 1 |
| Lleo, A | 1 |
| Ciancio, A | 1 |
| Di Marco, V | 1 |
| Brunetto, MR | 1 |
| Zuin, M | 1 |
| Andreone, P | 2 |
| Villa, E | 1 |
| Troshina, G | 1 |
| Calvaruso, V | 1 |
| Coco, B | 1 |
| Conti, F | 1 |
| Di Leo, A | 1 |
| Marzi, L | 1 |
| Boccaccio, V | 1 |
| Bollani, S | 1 |
| Maisonneuve, P | 1 |
| Bruno, S | 1 |
| Hassany, M | 1 |
| Elsharkawy, A | 1 |
| Maged, A | 1 |
| Mehrez, M | 1 |
| Asem, N | 1 |
| Gomaa, A | 1 |
| Mostafa, Z | 1 |
| Abbas, B | 1 |
| Soliman, M | 1 |
| Esmat, G | 1 |
| Flisiak, R | 1 |
| Janczewska, E | 1 |
| Łucejko, M | 1 |
| Karpińska, E | 1 |
| Zarębska-Michaluk, D | 1 |
| Nazzal, K | 1 |
| Bolewska, B | 1 |
| Białkowska, J | 1 |
| Berak, H | 1 |
| Fleischer-Stępniewska, K | 1 |
| Tomasiewicz, K | 1 |
| Karwowska, K | 1 |
| Piekarska, A | 1 |
| Tronina, O | 1 |
| Tuchendler, E | 1 |
| Garlicki, A | 1 |
| Revuelta-Herrero, JL | 1 |
| Giménez-Manzorro, A | 1 |
| Matilla-Peña, A | 1 |
| Herranz-Alonso, A | 1 |
| Sanjurjo-Sáez, M | 1 |
| Torres, HA | 1 |
| Economides, MP | 1 |
| Angelidakis, G | 1 |
| Hosry, J | 1 |
| Kyvernitakis, A | 1 |
| Mahale, P | 1 |
| Jiang, Y | 1 |
| Miller, E | 1 |
| Blechacz, B | 1 |
| Naing, A | 1 |
| Samaniego, F | 1 |
| Kaseb, A | 1 |
| Raad, II | 1 |
| Granwehr, BP | 1 |
| Preda, CM | 1 |
| Baicus, C | 1 |
| Sandra, I | 1 |
| Oproiu, A | 1 |
| Manuc, T | 1 |
| Constantinescu, I | 1 |
| Gavrila, D | 1 |
| Diculescu, M | 1 |
| Dumitru, R | 1 |
| Vasilescu, C | 1 |
| Tieranu, C | 1 |
| Istratescu, D | 1 |
| Voiosu, T | 1 |
| Manuc, M | 1 |
| Ramirez, S | 1 |
| Humes, D | 1 |
| Jensen, SB | 1 |
| Gottwein, JM | 1 |
| Bukh, J | 1 |
| Gamal, N | 1 |
| Vitale, G | 1 |
| Sugimoto, K | 1 |
| Kim, SR | 1 |
| Kim, SK | 1 |
| Imoto, S | 1 |
| Tohyama, M | 1 |
| Kim, KI | 1 |
| Ohtani, A | 1 |
| Hatae, T | 1 |
| Yano, Y | 1 |
| Hayashi, Y | 1 |
| Krastev, Z | 1 |
| Jelev, D | 1 |
| Antonov, K | 1 |
| Petkova, T | 1 |
| Atanasova, E | 1 |
| Zheleva, N | 1 |
| Tomov, B | 1 |
| Boyanova, Y | 1 |
| Mateva, L | 1 |
| Saab, S | 2 |
| Parisé, H | 2 |
| Virabhak, S | 2 |
| Wang, A | 2 |
| Marx, SE | 1 |
| Sanchez Gonzalez, Y | 1 |
| Misurski, D | 2 |
| Johnson, S | 2 |
| Gonzalez, YS | 1 |
| Juday, T | 1 |
| Nagata, H | 1 |
| Nakagawa, M | 1 |
| Nishimura-Sakurai, Y | 1 |
| Asano, Y | 1 |
| Tsunoda, T | 1 |
| Miyoshi, M | 1 |
| Kaneko, S | 1 |
| Goto, F | 1 |
| Otani, S | 1 |
| Kawai-Kitahata, F | 1 |
| Murakawa, M | 1 |
| Nitta, S | 1 |
| Itsui, Y | 1 |
| Azuma, S | 1 |
| Kakinuma, S | 1 |
| Tojo, N | 1 |
| Tohda, S | 1 |
| Asahina, Y | 1 |
| Watanabe, M | 1 |
| Kobayashi, M | 2 |
| Suzuki, F | 1 |
| Sezaki, H | 1 |
| Kawamura, Y | 1 |
| Hosaka, T | 1 |
| Saitoh, S | 1 |
| Suzuki, Y | 1 |
| Arase, Y | 1 |
| Ikeda, K | 1 |
| Hachicha, M | 1 |
| Botta-Fridlund, D | 1 |
| Weisberg, IS | 1 |
| Jacobson, IM | 1 |
| Calleja, JL | 1 |
| Crespo, J | 1 |
| Rincón, D | 1 |
| Ruiz-Antorán, B | 1 |
| Fernandez, I | 1 |
| Perelló, C | 1 |
| Gea, F | 1 |
| Lens, S | 1 |
| García-Samaniego, J | 1 |
| Sacristán, B | 1 |
| García-Eliz, M | 1 |
| Llerena, S | 1 |
| Pascasio, JM | 1 |
| Turnes, J | 1 |
| Torras, X | 1 |
| Morillas, RM | 1 |
| Llaneras, J | 1 |
| Serra, MA | 1 |
| Diago, M | 1 |
| Rodriguez, CF | 1 |
| Ampuero, J | 1 |
| Jorquera, F | 1 |
| Simon, MA | 1 |
| Arenas, J | 1 |
| Navascues, CA | 1 |
| Bañares, R | 1 |
| Muñoz, R | 1 |
| Albillos, A | 1 |
| Mariño, Z | 1 |
| Shen, Y | 1 |
| Lv, D | 1 |
| Wang, J | 1 |
| Yin, Y | 1 |
| Miao, F | 1 |
| Dou, F | 1 |
| Zhang, J | 1 |
| Esposito, V | 1 |
| Verdina, A | 1 |
| Manente, L | 1 |
| Spugnini, EP | 1 |
| Viglietti, R | 1 |
| Parrella, R | 1 |
| Pagliano, P | 1 |
| Parrella, G | 1 |
| Galati, R | 1 |
| De Luca, A | 1 |
| Baldi, A | 1 |
| Montesarchio, V | 1 |
| Chirianni, A | 1 |
| FALKSON, G | 1 |
| FALKSON, HC | 1 |
| Ezzat, S | 1 |
| Abdel-Hamid, M | 1 |
| Eissa, SA | 1 |
| Mokhtar, N | 1 |
| Labib, NA | 1 |
| El-Ghorory, L | 1 |
| Mikhail, NN | 1 |
| Abdel-Hamid, A | 1 |
| Hifnawy, T | 1 |
| Strickland, GT | 1 |
| Loffredo, CA | 1 |
| Lawson, D | 1 |
| Paik, WK | 1 |
| Morris, HP | 1 |
| Weinhouse, S | 1 |
| Pound, AW | 1 |
| Lawson, TA | 1 |
| Richardson, UI | 1 |
| Snodgrass, PJ | 1 |
| Nuzum, CT | 1 |
| Tashjian, AH | 1 |
| Mirvish, SS | 1 |
| Bhide, SV | 1 |
| De Luca, C | 1 |
| Valls, GB | 1 |
| Mason, JA | 1 |
| Sweeney, MJ | 1 |
| Hoffman, DH | 1 |
| Poore, GA | 1 |
| Tatibana, M | 1 |
| Shigesada, K | 1 |
| Hoogenraad, NJ | 1 |
| Lee, DC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Regression of Liver Fibrosis Assessed by Transient Elastography After Daclatasvir and Asunaprevir Combined Treatment in Advanced Fibrotic/Cirrhotic Patients With Chronic Hepatitis C Genotype 1b Infection[NCT02865369] | 103 participants (Anticipated) | Observational [Patient Registry] | 2016-09-30 | Not yet recruiting | |||
| Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC[NCT02771405] | Phase 3 | 150 participants (Anticipated) | Interventional | 2016-03-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for carbamates and Hepatocellular Carcinoma
| Article | Year |
|---|---|
New approaches in viraemic organ transplantation and antiviral therapies.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; Guani | 2020 |
ABT-450: a novel agent for the treatment of CHC genotype 1: focus on treatment-experienced patients.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Clinical Trials, | 2015 |
A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection.
Topics: Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Combinations; Genotype; Hepacivirus; H | 2017 |
The carcinogenic action and metabolism of urethan and N-hydroxyurethan.
Topics: Adenoma; Animals; Animals, Newborn; Body Fluids; Breast Neoplasms; Carbamates; Carcinogens; Carcinom | 1968 |
Two carbamyl phosphate synthetases of mammals: specific roles in control of pyrimidine and urea biosynthesis.
Topics: Adenosine Triphosphate; Animals; Arginine; Aspartic Acid; Carbamates; Carbon Isotopes; Carcinoma, He | 1972 |
45 other studies available for carbamates and Hepatocellular Carcinoma
| Article | Year |
|---|---|
Optimal Timing of Administration of Direct-acting Antivirals for Patients With Hepatitis C-associated Hepatocellular Carcinoma Undergoing Liver Transplantation.
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Administration S | 2021 |
Direct Relationship between Interleukin-10 Gene Polymorphism and Hepatocellular Carcinoma Complicated by Direct Acting Antiviral Treatment of Hepatitis C Virus.
Topics: Adult; Aged; Antiviral Agents; Ascites; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combina | 2021 |
Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents.
Topics: Administration, Oral; Aged; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, C | 2022 |
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.
Topics: Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Combinations; Drug Resistance, Viral; | 2019 |
Sustained virological response with 16-week glecaprevir/pibrentasvir after failure to sofosbuvir/velpatasvir in post-transplant severe HCV recurrence in HIV.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Combinations; Drug Res | 2019 |
Au(iii)-Proline derivatives exhibiting selective antiproliferative activity against HepG2/SB3 apoptosis-resistant cancer cells.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Carbamates; Carcinoma, Hepatocellular; Cell Li | 2019 |
Therapeutic Drug Monitoring-Guided Crushed Sofosbuvir-Velpatasvir Treatment: A Case Study.
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Combinations; Dr | 2020 |
Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens.
Topics: Adult; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; G | 2020 |
Hepatitis C virus relapse after successful treatment with direct-acting antivirals, followed by sarcomatous changes in hepatocellular carcinoma: a case report.
Topics: Aged; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Fatal Outcome; Hepacivirus; Hepatitis | 2020 |
Hypovascular tumors developed into hepatocellular carcinoma at a high rate despite the elimination of hepatitis C virus by direct-acting antivirals.
Topics: Aged; alpha-Fetoproteins; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Female; Genotype; | 2020 |
Cost-effectiveness analysis of sofosbuvir and velpatasvir in chronic hepatitis C patients with decompensated cirrhosis.
Topics: Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Genotype; Hepaciviru | 2021 |
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
Topics: Age Factors; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Com | 2021 |
Development of cell culture infectious clones for hepatitis C virus genotype 1b and transcription analysis of 1b-infected hepatoma cells.
Topics: Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cell Culture Techniques; Cell Line, Tumor; | 2021 |
Relationship of hepatitis B virus infection to the recurrence of hepatocellular carcinoma after direct acting antivirals.
Topics: Aged; Aged, 80 and over; Antibodies, Viral; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; | 2017 |
The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therap | 2017 |
Successful twice interrupted therapy of HCV infection in patients with cirrhosis with hepatocellular carcinoma before and after liver transplantation.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; D | 2017 |
Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Carbamates; Carcinoma, Hepatoc | 2017 |
Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation.
Topics: Aged; Antiviral Agents; Austria; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Therapy | 2018 |
Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Benzazepines; Biopsy; Carbamat | 2018 |
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma.
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cohort Studies; Drug | 2018 |
Hepatitis C virus treatment by direct-acting antivirals in successfully treated hepatocellular carcinoma and possible mutual impact.
Topics: Aged; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Egypt; Fem | 2018 |
Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real-world experience study.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyc | 2018 |
Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice.
Topics: 2-Naphthylamine; Aged; Anilides; Antineoplastic Agents; Antiviral Agents; Carbamates; Carcinoma, Hep | 2018 |
Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational Study.
Topics: Aged; Antiviral Agents; Benzimidazoles; Breast Neoplasms; Carbamates; Carcinoma, Hepatocellular; Dru | 2019 |
Recurrence rate of hepatocellular carcinoma in patients with treated hepatocellular carcinoma and hepatitis C virus-associated cirrhosis after ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin therapy.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Chemoembol | 2019 |
Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
Topics: Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Carrier Proteins; Cell Line, Tumor; Genotyp | 2014 |
Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Carbamates; Carcinoma, Hepatoc | 2015 |
Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropa | 2016 |
Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Carbama | 2016 |
Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocel | 2016 |
Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy.
Topics: Antigens, Neoplasm; Antiviral Agents; Biomarkers, Tumor; Carbamates; Carcinoma, Hepatocellular; Carr | 2016 |
Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Body Mass Index; Carbamates; Carcinoma, Hepatocell | 2016 |
[Sofosbuvir and daclatasvir combination therapy in hemodialysis patient with liver transplantation].
Topics: Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepatitis C; Hum | 2016 |
Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Carbama | 2017 |
GSI-I has a better effect in inhibiting hepatocellular carcinoma cell growth than GSI-IX, GSI-X, or GSI-XXI.
Topics: Amyloid Precursor Protein Secretases; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Fa | 2012 |
Amprenavir inhibits the migration in human hepatocarcinoma cell and the growth of xenografts.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Carbamates; Carcinoma, Hepatocel | 2013 |
CLINICAL EVALUATION OF BIS(2-CHLOROPROPYL)CARBAMIC ACID, ETHYL ESTER (6W54, NSC-53105).
Topics: Agranulocytosis; Antineoplastic Agents; Biomedical Research; Bone Marrow Diseases; Breast Neoplasms; | 1964 |
Associations of pesticides, HCV, HBV, and hepatocellular carcinoma in Egypt.
Topics: Adult; Carbamates; Carcinoma, Hepatocellular; Case-Control Studies; Egypt; Environmental Exposure; F | 2005 |
Carbamyl phosphate synthetases in rat liver neoplasms.
Topics: Animals; Carbamates; Carbon Radioisotopes; Carcinoma, Hepatocellular; Cell Division; Cell Fractionat | 1975 |
Carcinogenesis by carbamic acid esters and their binding to DNA.
Topics: Adenoma; Animals; Carbamates; Carcinoma, Hepatocellular; Croton Oil; Esters; Hemangioma; Leukemia, E | 1976 |
Establishment of a clonal strain of hepatoma cells which maintain in culture the five enzymes of the urea cycle.
Topics: Ammonia; Animals; Arginase; Arginine; Bucladesine; Carbamates; Carcinoma, Hepatocellular; Chromosome | 1974 |
Comparative study of metabolic profiles of primary hepatoma, regenerating liver, and liver in newborn Swiss mice.
Topics: Acetates; Aldehyde-Lyases; Amides; Animals; Animals, Newborn; Aspartic Acid; Carbamates; Carcinoma, | 1971 |
Drug effects on catalase activity in the mammalian cell. The role of the cell in drug action.
Topics: Acetamides; Aerobiosis; Alkenes; Allyl Compounds; Amides; Animals; Carbamates; Carcinoma; Carcinoma, | 1970 |
Enzymes in pyrimidine biosynthesis.
Topics: Amidohydrolases; Animals; Carbamates; Carcinoma, Hepatocellular; Fasting; Liver; Liver Neoplasms; Li | 1970 |
Effect of uridine on de novo pyrimidine biosynthesis in rat hepatoma cells in culture.
Topics: Amidohydrolases; Animals; Aspartate Carbamoyltransferase; Carbamates; Carbon Dioxide; Carbon Radiois | 1974 |